Developing innovative medicines for significant unmet medical needs
Kadmon is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. We are developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. We leverage our multi-disciplinary research and clinical development team members, who prior to joining Kadmon had brought more than 15 drugs to market, to identify and pursue a diverse portfolio of novel product candidates, both through in-licensing products and employing our small molecule and biologics platforms. We utilize our advanced understanding of the molecular mechanisms of disease to establish development paths for disease areas where significant unmet medical needs exist.
Kadmon Pharmaceuticals, our wholly-owned subsidiary, is our specialty-focused commercial operation and currently markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus (HCV) infection. Additionally, Kadmon Pharmaceuticals co-promotes and distributes products in a variety of therapeutic areas, including those indicated for the management of rare diseases. Please visit our Products page for a full listing of our product offerings.